{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:32:34Z","timestamp":1785465154996,"version":"3.56.0"},"reference-count":20,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T00:00:00Z","timestamp":1524700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015516","name":"Revance Therapeutics, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015516","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disord Clin Pract"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Injectable daxibotulinumtoxinA (an investigational botulinum toxin, RT002) may offer a more prolonged duration of response\u2014and therefore less frequent dosing\u2014than onabotulinumtoxinA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To perform a phase 2, open\u2010label, dose\u2010escalation study to assess the efficacy and safety of daxibotulinumtoxinA in cervical dystonia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Subjects with moderate\u2010to\u2010severe isolated cervical dystonia were enrolled in sequential cohorts to receive a single open\u2010label, intramuscular dose of injectable daxibotulinumtoxinA of up to 200 U (<jats:italic>n =<\/jats:italic> 12), 200\u2013300 U (<jats:italic>n =<\/jats:italic> 12), or 300\u2013450 U (<jats:italic>n =<\/jats:italic> 13; <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\">clinicaltrials.gov<\/jats:ext-link> identifier NCT02706795).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 33\/37 enrollees completed the trial. DaxibotulinumtoxinA was associated with mean reductions in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)\u2010Total score of 16.8 (38%) at week 4, 21.3 (50%) at week 6, and 12.8 (30%) at week 24. The proportion of subjects who were responders (achieved \u2265 20% reduction in TWSTRS\u2010Total score) was 94% at week 6 and 68% at week 24. The median duration of response (time until &gt; 20% of the improvement in TWSTRS\u2010Total score achieved at week 4 was no longer retained or re\u2010treatment was needed) was 25.3 weeks (95% CI, 20.14\u201326.14 weeks). There were no serious adverse events and there was no apparent dose\u2010related increase in the incidence of adverse events. The most common treatment\u2010related adverse events were dysphagia (14%) and injection site erythema (8%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Preliminary assessments suggest that injectable daxibotulinumtoxinA at doses up to 450 U is well tolerated and may offer prolonged efficacy in the treatment of cervical dystonia. Further studies involving larger numbers of patients are now warranted.<\/jats:p><\/jats:sec>","DOI":"10.1002\/mdc3.12613","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T06:28:11Z","timestamp":1521095291000},"page":"273-282","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose\u2010Escalation Multicenter Study"],"prefix":"10.1002","volume":"5","author":[{"given":"Joseph","family":"Jankovic","sequence":"first","affiliation":[{"name":"Parkinson's Disease Center and Movement Disorders Clinic Department of Neurology, Baylor College of Medicine Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Truong","sequence":"additional","affiliation":[{"name":"The Parkinson's and Movement Disorder Institute Fountain Valley CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul T.","family":"Patel","sequence":"additional","affiliation":[{"name":"Kansas City Bone &amp; Joint Clinic Overland Park KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Brashear","sequence":"additional","affiliation":[{"name":"Wake Forest Baptist Medical Center Winston Salem NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Evatt","sequence":"additional","affiliation":[{"name":"Acting Chief, Neurology Department of Veterans Affairs Medical Center, Atlanta, GA and Department of Neurology Emory University Atlanta GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman G.","family":"Rubio","sequence":"additional","affiliation":[{"name":"Revance Therapeutics, Inc. Newark CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad K.","family":"Oh","sequence":"additional","affiliation":[{"name":"Revance Therapeutics, Inc. Newark CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Snyder","sequence":"additional","affiliation":[{"name":"Revance Therapeutics, Inc. Newark CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gill","family":"Shears","sequence":"additional","affiliation":[{"name":"Write on Target Ltd. Leighton Buzzard UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Comella","sequence":"additional","affiliation":[{"name":"Rush University Medical Center Chicago IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,26]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00035"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27072"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S106560"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.5334\/tohm.185","article-title":"Botulinum toxin therapy for cervical dystonia: the science of dosing","volume":"4","author":"Evidente VG","year":"2014","journal-title":"Tremor Other Hyperkinet Mov (NY)"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001206"},{"key":"e_1_2_8_7_1","unstructured":"Clinicaltrials.govwebsite. Available at:https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=Revance&cntry1=&state1=&recrs=#wrapper. Accessed July 20 2017."},{"key":"e_1_2_8_8_1","unstructured":"GlogauRG WaughJM.Preclinical transcutaneous flux experiments using a macromolecule transport system (MTS) peptide for delivery of botulinum toxin type A. Poster presented at the 66th annual meeting of the American Academy of Dermatology San Antonio Texas February 1\u20135 2008. Available at:http:\/\/www.revance.com\/pdfs\/Preclinical\u2010transcutaneous\u2010flux\u2010experiment\u2010type\u2010a.pdf. Accessed August 14 2017."},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2011.05.012"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000276"},{"key":"e_1_2_8_11_1","unstructured":"Norwegian Health Informatics AS website.Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). Available at:http:\/\/nevro.legehandboka.no\/imagevault\/publishedmedia\/jipv0xim2ibb749yalju\/6454\u20102\u2010twstrs.pdf. Accessed July 19 2017."},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000142962.11881.26"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2011.05.041"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.7.1439"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20403"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26760"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2017.02.042"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-14-91"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.64.1.6"},{"key":"e_1_2_8_20_1","article-title":"Prospective study evaluating incobotulinumtoxinA for cervical dystonia or blepharospasm: interim results from the first 145 subjects with cervical dystonia","volume":"3","author":"Fernandez HH","year":"2013","journal-title":"Tremor Other Hyperkinet Mov (NY)"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e31826538c7"}],"container-title":["Movement Disorders Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmdc3.12613","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.12613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:03:52Z","timestamp":1760961832000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mdc3.12613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,26]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1002\/mdc3.12613"],"URL":"https:\/\/doi.org\/10.1002\/mdc3.12613","archive":["Portico"],"relation":{},"ISSN":["2330-1619","2330-1619"],"issn-type":[{"value":"2330-1619","type":"print"},{"value":"2330-1619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,26]]},"assertion":[{"value":"2017-11-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}